Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-10-19

INCYTE CORP (INCY)

CEO William Meury was paid $32,085,952 in fiscal year 2025, the 92nd percentile of its disclosed peer group (SEC filing 0000879169-26-000031 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$32,085,952
William Meury total, FY2025
92nd
CEO pay percentile vs peers
110.47:1
CEO-to-median pay ratio
83.86%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- William Meury (Chief Executive Officer), FY2025 total compensation $32,085,952 (base salary $647,260) [exec_comp, SEC accession 0000879169-26-000031, filed 2026-04-28]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

INCY's next annual pay disclosure, estimated April 27, 2027.est. Filing ↗

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
William Meury$647,260$0$27,509,657$2,573,998$1,300,000$0$55,037$32,085,952
Chief Executive Officer
Mohamed Issa690,4111,000,0007,870,118450,983533,610047,66010,592,782
Executive Vice President and Head of U.S. Commercial
Pablo Cagnoni966,51604,952,3781,815,1591,007,027097,8818,838,961
President and Global Head of Research and Development
Herve Hoppenot1,392,49901,971,9751,694,0341,026,0720295,9456,380,525
Former President and Chief Executive Officer
Steven Stein835,06703,466,6751,270,592696,054035,7846,304,172
Executive Vice President, Chief Medical Officer and Head of Late-stage Development
Christiana Stamoulis520,83903,136,4681,149,58800129,6554,936,550
Former Executive Vice President and Chief Financial Officer
Thomas Tray358,1890305,897154,623149,423022,236990,368
Vice President, Chief Accounting Officer and Principal Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
William Meury$32,085,952———
Mohamed Issa10,592,782———
Pablo Cagnoni8,838,9617,904,299—↑ +934,662
Herve Hoppenot6,380,52517,459,54616,659,526↓ −11,079,021
Steven Stein6,304,1725,979,828—↑ +324,344
Christiana Stamoulis4,936,5505,397,757—↓ −461,207
Thomas Tray990,368———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read INCYTE CORP's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper INCY reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the INCYTE CORP Peer Teardown Report

$32,085,952 William Meury total, FY2025

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of October 19, 2026 · Source: 0000879169-26-000031 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for INCY

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
INCYon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order INCY

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against INCY
29 companies name INCY as a compensation peer

Each company listed discloses INCY in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named INCY in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Get the INCYTE CORP Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2025 total
Christiana StamoulisExecutive$4,936,550
Mohamed IssaEVP$10,592,782
Pablo CagnoniPresident$8,838,961
Steven SteinEVP$6,304,172
Thomas TrayExecutive$990,368
William MeuryCEO$32,085,952
Herve HoppenotExecutive$6,380,525
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2025 total
Edmund P. HarriganIndependent Director$539,638
Jacqualyn A. FouseIndependent Director$524,638
Jean-Jacques BienaiméIndependent Director$536,138
Julian C. BakerIndependent Director$573,138
Katherine A. HighIndependent Director$511,138
Otis W. BrawleyIndependent Director$511,138
Paul J. ClancyIndependent Director$538,138
Susanne SchaffertIndependent Director$523,138
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Suketu UpadhyayEVP & Chief Financial Officer2026-05-04A13,171$0$0Derivative, Class A CommonForm 4 ↗
Suketu UpadhyayEVP & Chief Financial Officer2026-05-04A38,42900Derivative, Class A CommonForm 4 ↗
Suketu UpadhyayEVP & Chief Financial Officer2026-05-04A26,34300CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-05-06A44,12400CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-05-06A31,51700CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-05-08A15,000851,267,950CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-05-08D15,00000Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-05-08D15,00000Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-05-08A15,000851,267,950CommonForm 4 ↗
Paul J. ClancyDirector2026-05-19A15,000851,267,950CommonForm 4 ↗
Paul J. ClancyDirector2026-05-19D15,000951,423,950CommonForm 4 ↗
Paul J. ClancyDirector2026-05-19D15,00000Derivative, Class A CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-05-26D15,00000Derivative, Class A CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-05-26D13,059971,268,029CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-05-26A15,000851,267,950CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-05-26D2,05197199,665CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-06-01D25,469962,434,582CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-06-04A2,63984221,227CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-06-04D2,63900Derivative, Class A CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-06-04D2,639100263,900CommonForm 4 ↗
Otis W. BrawleyDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
Otis W. BrawleyDirector2026-06-08A1,64200CommonForm 4 ↗
Katherine A. HighDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
Katherine A. HighDirector2026-06-08A1,64200CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-08A1,64200CommonForm 4 ↗
Paul J. ClancyDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
Jacqualyn A. FouseDirector2026-06-08A1,64200CommonForm 4 ↗
Paul J. ClancyDirector2026-06-08A1,64200CommonForm 4 ↗
Edmund P. HarriganDirector2026-06-08A1,64200CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-06-08A1,64200CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-06-08A1,64200CommonForm 4 ↗
Jacqualyn A. FouseDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
Edmund P. HarriganDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-06-30A40000CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-06-30A40000CommonForm 4 ↗
Paul J. ClancyDirector2026-06-30A25211328,567CommonForm 4 ↗
Edmund P. HarriganDirector2026-06-30A25511328,907CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-02D2,177117254,404CommonForm 4 ↗
William MeuryDirector2026-07-02D4,779117558,474CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-07-02D47711755,742CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-02D35011740,901CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-14D21,8301152,507,830CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-07-14D69211579,497CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-14D43711550,203CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-07-14D17,9691152,064,279CommonForm 4 ↗
Mohamed IssaEVP, Head of U.S. Commercial2026-07-15D1,099115126,484CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-15D3,088115355,398CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-15D28,2371133,192,193CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-15D1,512115174,016CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-07-15D4,950115569,696CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-07-15D1,098115126,369CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-07-16A33,50800Derivative, Class A CommonForm 4 ↗
Mohamed IssaEVP, Head of U.S. Commercial2026-07-16A19,64300Derivative, Class A CommonForm 4 ↗
William MeuryDirector2026-07-16A80,42100Derivative, Class A CommonForm 4 ↗
Richard A. HoffmanEVP & General Counsel2026-07-16A7,39500CommonForm 4 ↗
Richard A. HoffmanEVP & General Counsel2026-07-16A18,48700Derivative, Class A CommonForm 4 ↗
David H. GardnerEVP, Chief Strategy Officer2026-07-16A18,48700Derivative, Class A CommonForm 4 ↗
Mohamed IssaEVP, Head of U.S. Commercial2026-07-16D1,093115125,706CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-07-16A13,40300CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-07-16A57,86100Derivative, Class A CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-16A24,49600Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-16A25,53800Derivative, Class A CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-16A9,79800CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-16D1,877115215,348CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-07-16A4,07900Derivative, Class A CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-07-16A2,83400CommonForm 4 ↗
William MeuryDirector2026-07-16A26,80700CommonForm 4 ↗
David H. GardnerEVP, Chief Strategy Officer2026-07-16A7,39500CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-16A14,79000Derivative, Class A CommonForm 4 ↗
William MeuryDirector2026-07-16A77,14800Derivative, Class A CommonForm 4 ↗
Richard A. HoffmanEVP & General Counsel2026-07-16A31,92300Derivative, Class A CommonForm 4 ↗
Ramitpal K. BasiEVP, Human Resources2026-07-16A21,54800Derivative, Class A CommonForm 4 ↗
Mohamed IssaEVP, Head of U.S. Commercial2026-07-16A33,91800Derivative, Class A CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-16A42,29800Derivative, Class A CommonForm 4 ↗
Ramitpal K. BasiEVP, Human Resources2026-07-16A4,99100CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-16A5,91600CommonForm 4 ↗
David H. GardnerEVP, Chief Strategy Officer2026-07-16A31,92300Derivative, Class A CommonForm 4 ↗
Ramitpal K. BasiEVP, Human Resources2026-07-16A12,47900Derivative, Class A CommonForm 4 ↗
Mohamed IssaEVP, Head of U.S. Commercial2026-07-16A7,85700CommonForm 4 ↗
Lee HeesonEVP, Head of Incyte Intl2026-07-23A15,42300Derivative, Class A CommonForm 4 ↗
Lee HeesonEVP, Head of Incyte Intl2026-07-23A13,49800Derivative, Class A CommonForm 4 ↗
Michael James MorrisseyEVP, Head of Tech. Operations2026-07-23A6,42600Derivative, Class A CommonForm 4 ↗
Michael James MorrisseyEVP, Head of Tech. Operations2026-07-23A8,99900Derivative, Class A CommonForm 4 ↗
Dividend-equivalent accruals2026-07-31—3,696——1 insider, 4 accrual rows
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,29300Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,62300Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D9,45900Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D3,14800Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,70900Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,28400Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,91800Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,293119273,807CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D32612239,671CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D6,171119737,003CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,187119261,281CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D5,332119636,747CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D14,6611191,751,403CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A1,64381132,262CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A2,86478222,447CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A2,62375196,148CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A9,45972683,602CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A2,07272149,039CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A3,14869216,016CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A2,28464146,747CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A2,91861178,523CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-07-31D15,8881201,901,794CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D1,643120196,355CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D4,695119560,536CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D1,642119196,022CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A2,70962167,308CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,62300Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D3,02300Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,86400Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,07200Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D8512210,386CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,864119341,962CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A32610534,370CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A851069,050CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A2,29391207,654CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A1,64285139,586CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A2,62384219,230CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A3,02383251,514CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-08-03D6,055120729,204CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-08-03A6,055105638,379CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-08-03D6,05500Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-08-05D2,20700Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-08-05D2,207124273,646CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-08-05A2,207106234,979CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-08-05D10,6401231,305,422CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-08-12D10,8031201,296,792CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-08-19D10,8011261,356,174CommonForm 4 ↗
Ramitpal K. BasiEVP, Human Resources2026-08-25D50413065,379CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15D6,47700Derivative, Class A CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15D4,55100Derivative, Class A CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15D2,95700Derivative, Class A CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15D13,9851201,685,053CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15D9,2331211,112,577CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15A6,47764416,147CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15A4,55161278,430CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15A9,23372664,130CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15D9,23300Derivative, Class A CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15A2,95762182,624CommonForm 4 ↗
David H. GardnerEVP, Chief Strategy Officer2026-09-22D920127116,776CommonForm 4 ↗
Paul J. ClancyDirector2026-09-30A20312124,634CommonForm 4 ↗
Edmund P. HarriganDirector2026-09-30A20612124,998CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-09-30A32200CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-09-30A32200CommonForm 4 ↗
Lee HeesonEVP, Head of Incyte Intl2026-10-01D46311754,236CommonForm 4 ↗
Dividend-equivalent accruals2026-10-15—2,642——1 insider, 4 accrual rows
Pablo CagnoniPresident, Global Head of R&D2026-10-15D2,642113297,780CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-10-15A9256459,431CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-10-15A4556127,837CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-10-15A4236226,124CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-10-15A8397260,349CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 163 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Suketu UpadhyayEVP & Chief Financial Officer2026-05-04A13,171$0$0Derivative, Class A CommonForm 4 ↗
Suketu UpadhyayEVP & Chief Financial Officer2026-05-04A38,42900Derivative, Class A CommonForm 4 ↗
Suketu UpadhyayEVP & Chief Financial Officer2026-05-04A26,34300CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-05-06A44,12400CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-05-06A31,51700CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-05-08A15,000851,267,950CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-05-08D15,00000Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-05-08D15,00000Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-05-08A15,000851,267,950CommonForm 4 ↗
Paul J. ClancyDirector2026-05-19A15,000851,267,950CommonForm 4 ↗
Paul J. ClancyDirector2026-05-19D15,000951,423,950CommonForm 4 ↗
Paul J. ClancyDirector2026-05-19D15,00000Derivative, Class A CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-05-26D15,00000Derivative, Class A CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-05-26D13,059971,268,029CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-05-26A15,000851,267,950CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-05-26D2,05197199,665CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-06-01D25,469962,434,582CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-06-04A2,63984221,227CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-06-04D2,63900Derivative, Class A CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-06-04D2,639100263,900CommonForm 4 ↗
Otis W. BrawleyDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
Otis W. BrawleyDirector2026-06-08A1,64200CommonForm 4 ↗
Katherine A. HighDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
Katherine A. HighDirector2026-06-08A1,64200CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-08A1,64200CommonForm 4 ↗
Paul J. ClancyDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
Jacqualyn A. FouseDirector2026-06-08A1,64200CommonForm 4 ↗
Paul J. ClancyDirector2026-06-08A1,64200CommonForm 4 ↗
Edmund P. HarriganDirector2026-06-08A1,64200CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-06-08A1,64200CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-06-08A1,64200CommonForm 4 ↗
Jacqualyn A. FouseDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
Edmund P. HarriganDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-06-08A6,11100Derivative, Class A CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-06-30A40000CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-06-30A40000CommonForm 4 ↗
Paul J. ClancyDirector2026-06-30A25211328,567CommonForm 4 ↗
Edmund P. HarriganDirector2026-06-30A25511328,907CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-02D2,177117254,404CommonForm 4 ↗
William MeuryDirector2026-07-02D4,779117558,474CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-07-02D47711755,742CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-02D35011740,901CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-14D21,8301152,507,830CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-07-14D69211579,497CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-14D43711550,203CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-07-14D17,9691152,064,279CommonForm 4 ↗
Mohamed IssaEVP, Head of U.S. Commercial2026-07-15D1,099115126,484CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-15D3,088115355,398CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-15D28,2371133,192,193CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-15D1,512115174,016CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-07-15D4,950115569,696CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-07-15D1,098115126,369CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-07-16A33,50800Derivative, Class A CommonForm 4 ↗
Mohamed IssaEVP, Head of U.S. Commercial2026-07-16A19,64300Derivative, Class A CommonForm 4 ↗
William MeuryDirector2026-07-16A80,42100Derivative, Class A CommonForm 4 ↗
Richard A. HoffmanEVP & General Counsel2026-07-16A7,39500CommonForm 4 ↗
Richard A. HoffmanEVP & General Counsel2026-07-16A18,48700Derivative, Class A CommonForm 4 ↗
David H. GardnerEVP, Chief Strategy Officer2026-07-16A18,48700Derivative, Class A CommonForm 4 ↗
Mohamed IssaEVP, Head of U.S. Commercial2026-07-16D1,093115125,706CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-07-16A13,40300CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-07-16A57,86100Derivative, Class A CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-16A24,49600Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-16A25,53800Derivative, Class A CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-16A9,79800CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-16D1,877115215,348CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-07-16A4,07900Derivative, Class A CommonForm 4 ↗
Thomas TrayPrincipal Accounting Officer2026-07-16A2,83400CommonForm 4 ↗
William MeuryDirector2026-07-16A26,80700CommonForm 4 ↗
David H. GardnerEVP, Chief Strategy Officer2026-07-16A7,39500CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-16A14,79000Derivative, Class A CommonForm 4 ↗
William MeuryDirector2026-07-16A77,14800Derivative, Class A CommonForm 4 ↗
Richard A. HoffmanEVP & General Counsel2026-07-16A31,92300Derivative, Class A CommonForm 4 ↗
Ramitpal K. BasiEVP, Human Resources2026-07-16A21,54800Derivative, Class A CommonForm 4 ↗
Mohamed IssaEVP, Head of U.S. Commercial2026-07-16A33,91800Derivative, Class A CommonForm 4 ↗
Steven SteinCMO & Head of Late-Stage Dev.2026-07-16A42,29800Derivative, Class A CommonForm 4 ↗
Ramitpal K. BasiEVP, Human Resources2026-07-16A4,99100CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-16A5,91600CommonForm 4 ↗
David H. GardnerEVP, Chief Strategy Officer2026-07-16A31,92300Derivative, Class A CommonForm 4 ↗
Ramitpal K. BasiEVP, Human Resources2026-07-16A12,47900Derivative, Class A CommonForm 4 ↗
Mohamed IssaEVP, Head of U.S. Commercial2026-07-16A7,85700CommonForm 4 ↗
Lee HeesonEVP, Head of Incyte Intl2026-07-23A15,42300Derivative, Class A CommonForm 4 ↗
Lee HeesonEVP, Head of Incyte Intl2026-07-23A13,49800Derivative, Class A CommonForm 4 ↗
Michael James MorrisseyEVP, Head of Tech. Operations2026-07-23A6,42600Derivative, Class A CommonForm 4 ↗
Michael James MorrisseyEVP, Head of Tech. Operations2026-07-23A8,99900Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D8500Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D32600Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,29300Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D1,64200Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,62300Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D9,45900Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D3,14800Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,70900Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,28400Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,91800Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,293119273,807CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D32612239,671CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D6,171119737,003CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,187119261,281CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D5,332119636,747CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D14,6611191,751,403CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A1,64381132,262CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A2,86478222,447CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A2,62375196,148CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A9,45972683,602CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A2,07272149,039CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A3,14869216,016CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A2,28464146,747CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A2,91861178,523CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-07-31D15,8881201,901,794CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D1,64300Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D1,643120196,355CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D4,695119560,536CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D1,642119196,022CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A2,70962167,308CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,62300Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D3,02300Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,86400Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,07200Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D8512210,386CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31D2,864119341,962CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A32610534,370CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A851069,050CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A2,29391207,654CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A1,64285139,586CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A2,62384219,230CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-07-31A3,02383251,514CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-08-03D6,055120729,204CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-08-03A6,055105638,379CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-08-03D6,05500Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-08-05D2,20700Derivative, Class A CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-08-05D2,207124273,646CommonForm 4 ↗
Patrick A. MayesEVP & Chief Scientific Officer2026-08-05A2,207106234,979CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-08-05D10,6401231,305,422CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-08-12D10,8031201,296,792CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-08-19D10,8011261,356,174CommonForm 4 ↗
Ramitpal K. BasiEVP, Human Resources2026-08-25D50413065,379CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15D6,47700Derivative, Class A CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15D4,55100Derivative, Class A CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15D2,95700Derivative, Class A CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15D13,9851201,685,053CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15D9,2331211,112,577CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15A6,47764416,147CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15A4,55161278,430CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15A9,23372664,130CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15D9,23300Derivative, Class A CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-09-15A2,95762182,624CommonForm 4 ↗
David H. GardnerEVP, Chief Strategy Officer2026-09-22D920127116,776CommonForm 4 ↗
Paul J. ClancyDirector2026-09-30A20312124,634CommonForm 4 ↗
Edmund P. HarriganDirector2026-09-30A20612124,998CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-09-30A32200CommonForm 4 ↗
BAKER BROS. ADVISORS LPDirector2026-09-30A32200CommonForm 4 ↗
Lee HeesonEVP, Head of Incyte Intl2026-10-01D46311754,236CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-10-15D92500Derivative, Class A CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-10-15D45500Derivative, Class A CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-10-15D42300Derivative, Class A CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-10-15D83900Derivative, Class A CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-10-15D2,642113297,780CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-10-15A9256459,431CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-10-15A4556127,837CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-10-15A4236226,124CommonForm 4 ↗
Pablo CagnoniPresident, Global Head of R&D2026-10-15A8397260,349CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
William MeuryPSU2025-07-0254,152108,303—216,606$9,276,152
Thomas TrayPSU2025-07-15—4,482—13305,897
Pablo CagnoniOPTION2025-07-15——39,471—901,981
Mohamed IssaPSU2025-07-1510,96221,923—43,8461,877,705
Mohamed IssaPSU2025-07-15—8,769—13598,484
Mohamed IssaRSU2025-01-06——48,671—3,499,932
Christiana StamoulisPSU2025-07-15—11,107—13758,053
Steven SteinPSU2025-07-1515,34630,692—61,3842,628,770
Christiana StamoulisPSU2025-07-1513,88527,769—55,5382,378,415
Hervé HoppenotOPTION2025-06-26——11—428,997
Hervé HoppenotOPTION2025-01-17——10—1,258,171
Hervé HoppenotPSU2025-06-26—6,016—13425,993
Hervé HoppenotPSU2025-06-269,02518,050—36,1001,545,982
Mohamed IssaPSU2025-06-30—27,812—141,893,997
Steven SteinPSU2025-07-15—12,277—13837,905
Mohamed IssaOPTION2025-07-15——19,735—450,983
Thomas TrayOPTION2025-01-17——3,432—77,790
William MeuryPSU2025-07-02—125,000—500,00015,772,500
Christiana StamoulisOPTION2025-07-15——24,998—571,250
Pablo CagnoniPSU2025-07-15—17,538—131,196,969
William MeuryRSU2025-07-02——36,101—2,461,005
Pablo CagnoniPSU2025-07-1521,92343,846—87,6923,755,409
Steven SteinOPTION2025-01-17——28,202—639,221
William MeuryOPTION2025-06-26——110,630—2,573,998
Thomas TrayOPTION2025-07-15——3,362—76,833
Christiana StamoulisOPTION2025-01-17——25,516—578,338
Steven SteinOPTION2025-07-15——27,629—631,371
Pablo CagnoniOPTION2025-01-17——40,289—913,178
Hervé HoppenotOPTION2016-01-07——15—6,866
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
William Meury$2,461,005$25,048,652$2,573,99883.3%
Thomas Tray0305,897154,62366.4%
Pablo Cagnoni04,952,3781,815,15973.2%
Mohamed Issa3,499,9324,370,186450,98352.5%
Christiana Stamoulis03,136,4681,149,58873.2%
Steven Stein03,466,6751,270,59273.2%
Hervé Hoppenot01,971,9751,694,03453.8%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
HoppenotOption11,94277.67—
Pablo CagnoniRSU14,889—1,470,587
HoppenotRSU107,960—10,663,209
HoppenotRSU249,086—24,602,225
Pablo CagnoniPSU229,661—22,683,617
Pablo CagnoniRSU192,400—19,003,348
William MeuryRSU125,000—12,346,250
HoppenotRSU123,076—12,156,217
Pablo CagnoniRSU117,643—11,619,599
William MeuryRSU108,303—10,697,087
Steven SteinRSU99,269—9,804,799
HoppenotPSU70,643—6,977,409
Pablo CagnoniRSU49,627—4,901,659
Mohamed IssaRSU48,671—4,807,235
Pablo CagnoniRSU43,846—4,330,669
William MeuryRSU36,101—3,565,696
Pablo CagnoniRSU17,538—1,732,228
Steven SteinRSU34,739—3,431,171
Steven SteinPSU34,203—3,378,230
Steven SteinRSU33,838—3,342,179
Steven SteinRSU30,692—3,031,449
Pablo CagnoniRSU4,834—477,454
HoppenotRSU29,468—2,910,554
Mohamed IssaRSU27,812—2,746,991
Pablo CagnoniRSU24,170—2,387,271
Mohamed IssaRSU21,923—2,165,335
HoppenotOption12,60883.2—
HoppenotRSU20,684—2,042,959
HoppenotRSU18,050—1,782,799
Thomas TrayPSU15,166—1,497,945
HoppenotRSU14,475—1,429,696
Steven SteinRSU12,277—1,212,599
Steven SteinRSU10,422—1,029,381
Mohamed IssaRSU8,769—866,114
Steven SteinRSU6,768—668,475
HoppenotRSU6,016—594,200
Thomas TrayRSU1,038—102,523
Steven SteinRSU4,736—467,775
Thomas TrayRSU3,805—375,820
Thomas TrayRSU4,482—442,687
Thomas TrayRSU3,008—297,100
Thomas TrayRSU2,833—279,815
William MeuryOption110,63070.81—
HoppenotOption35,84961.76—
HoppenotOption38,62161.18—
HoppenotOption39,51964.25—
HoppenotOption35,85171.93—
HoppenotOption18,43870.81—
Pablo CagnoniOption8,02661.76—
Pablo CagnoniOption8,64761.18—
Pablo CagnoniOption28,68364.25—
Pablo CagnoniOption26,02171.93—
Pablo CagnoniOption39,47168.25—
Mohamed IssaOption19,73568.25—
Steven SteinOption3,74377.67—
Steven SteinOption3,95283.2—
Steven SteinOption11,23661.76—
Steven SteinOption12,10561.18—
Steven SteinOption20,07864.25—
Steven SteinOption18,21571.93—
Steven SteinOption27,62968.25—
Thomas TrayOption41077.67—
Thomas TrayOption43383.2—
Thomas TrayOption2,45468.25—
Thomas TrayOption1,66561.76—
Thomas TrayOption1,79461.18—
Thomas TrayOption2,44464.25—
Thomas TrayOption2,21771.93—
05

Incentive-plan design — the Compensation Discussion & Analysis

Incyte's compensation program is designed to attract and retain highly qualified directors and executives by aligning compensation with peer companies. It reflects the time, effort, expertise, and accountability required for active board and executive service.

CEO STI target (% of salary)110%
CEO LTI target (% of salary)—
Independent consultantAon
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-08145,851,78428,078,013290,89183.86%Passed
20252025-04-11153,838,97213,020,842571,30192.2%Passed
20242024-06-12171,688,04019,939,207336,17289.59%Passed
20232023-06-14169,320,95223,663,412241,86087.74%Passed
20222022-06-15170,569,04917,789,07582,01290.56%Passed
20212021-05-13175,778,84114,039,03889,35692.6%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0883.86%a
20252025-04-1192.2%b
20242024-06-1289.59%c

a. Approved under the standard stated in the filing — “abstentions and broker non-votes do not count as votes cast.”.

b. Approved under the standard stated in the filing — “abstentions and broker non-votes do not count as votes cast.”.

c. Approved under the standard stated in the filing — “abstentions and broker non-votes do not count as votes cast.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)110.47 : 1
CEO total compensation$32,688,692
Median employee compensation$295,914
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Julian C. BakerIndependent · Nominating and Corporate Governance (Chair) · Compensation$0$308,436$264,702$0$0$573,138
Edmund P. HarriganIndependent · Science and Technology (Chair) · Audit0274,936264,70200539,638
Paul J. ClancyIndependent · Audit (Chair) · Compensation0273,436264,70200538,138
Jean-Jacques BienaiméIndependent · Compensation (Chair) · Nominating and Corporate Governance95,000176,436264,702——536,138
Jacqualyn A. FouseIndependent · Audit · Nominating and Corporate Governance83,500176,436264,70200524,638
Susanne SchaffertIndependent · Compensation82,000176,436264,70200523,138
Otis W. BrawleyIndependent · Science and Technology70,000176,436264,70200511,138
Katherine A. HighIndependent · Science and Technology70,000176,436264,70200511,138
William J. MeuryEmployee director000—00
Hervé HoppenotEmployee director · Departed during FY000—00
09

Board fee structure and ownership guideline

Annual cash retainer$65,000
Annual equity retainer$400,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)25,000 / 25,000 / 20,000
Stock ownership guideline$390,000
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$400,500
Equity awards (grant-date value)$1,738,988
All other compensation$0
Total cost of the board$2,139,488

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies INCYTE CORP names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including INCYTE CORP.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Exelixis, Inc.2025Michael Morrissey$1,306,040$30,539,552$0$1,382,591$33,239,183
2INCYTE CORP2025William Meury647,26027,509,6572,573,9981,300,00032,085,952
3Biogen Inc.2025Christopher Viehbacher1,727,88518,368,87503,190,87523,646,004
4PTC Therapeutics, Inc.2025Matthew Klein958,50016,593,8004,399,7601,294,00023,266,326
5BioMarin Pharmaceutical Inc.2025Alexander Hardy1,130,76916,833,6291,909,3101,644,50021,927,563
6Moderna, Inc.2025Stéphane Bancel1,677,7396,897,4556,897,4254,302,36019,932,217
7Jazz Pharmaceuticals plc2025Renee Gala1,003,26916,138,43301,980,00019,151,558
8United Therapeutics Corporation2025Martine Rothblatt1,545,0056,067,9906,075,8044,281,87518,038,972
9BeOne Medicines Ltd.2025John Oyler1,133,00011,249,6153,749,9671,676,84017,943,521
10Natera, Inc.2025Steven Chapman853,71012,979,55801,114,15114,957,319
11Alnylam Pharmaceuticals, Inc.2025Yvonne Greenstreet1,404,2005,512,5004,363,3803,562,50014,867,600
12Neurocrine Biosciences, Inc.2025Kyle Gano920,0005,750,0235,750,006013,448,935
13Illumina, Inc.2025Jacob Thaysen1,000,0008,763,12201,155,00011,018,895
—argenx SE——————not in coverage universe
—Genmab A/S——————not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
INCYTE CORP138.6%Performance Shares 60 · RSU 40Yes — relative total shareholder return (TSR)Aon
Alnylam Pharmaceuticals, Inc.200%PSU 50 · RSU 25 · Option 25NoPay Governance
argenx SEnot disclosednot disclosednot disclosednot disclosed
BeOne Medicines Ltd.148%PSU 50 · Options 25 · RSU 25NoPay Governance
Biogen Inc.127%PSU 60 · RSU 40YesPay Governance
BioMarin Pharmaceutical Inc.130%PSU 66 · RSU 21 · Options 13Yes — Relative TSRAon Human Capital Solutions
Exelixis, Inc.105%PSU 50 · RSU 50Yes — 2025 Relative TSR GoalAon
Genmab A/Snot disclosednot disclosednot disclosednot disclosed
Illumina, Inc.1155%not disclosedYes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology IndexAon (Aon's Human Capital Practice, a division of Aon, plc)
Jazz Pharmaceuticals plc150%PSU 50 · RSU 50Yes — Relative TSRAon
Moderna, Inc.170%PSU 50 · Options 50NoPay Governance LLC
Natera, Inc.131.1%PSU 50 · RSU 50NoAon
Neurocrine Biosciences, Inc.105%Options 50 · PSU 30 · RSU 20NoFrederic W. Cook & Co., Inc.
PTC Therapeutics, Inc.not disclosedOption 50 · RSU 50Yes — TSR relative to Nasdaq Biotechnology IndexFrederic W. Cook & Co., Inc.
United Therapeutics Corporation221%PSO 50 · PSU 50NoAon

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at INCYTE CORP in fiscal 2025?
As disclosed, William Meury (Chief Executive Officer) was the highest-paid executive at INCYTE CORP in fiscal 2025, with total compensation of $32,085,952.
How does INCYTE CORP's chief executive pay compare to its disclosed peer group?
As disclosed, William Meury's total compensation ranked at the 92nd percentile of INCYTE CORP's disclosed peer group.
What is INCYTE CORP's CEO-to-median employee pay ratio?
As disclosed, INCYTE CORP's CEO-to-median employee pay ratio was 110.47:1.
How did shareholders vote on INCYTE CORP's executive compensation?
As disclosed, 83.86% of shareholders supported INCYTE CORP's executive compensation in the latest say-on-pay vote.
How much does INCYTE CORP spend in total on board compensation for fiscal 2025?
As disclosed, INCYTE CORP reported total board compensation of $2,139,488 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, William MeuryDEF 14A2026-04-280000879169-26-000031Section “Summary Compensation Table”. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827
2Section 01, Mohamed IssaDEF 14A2026-04-280000879169-26-000031Section “Summary Compensation Table”. As printed: 10,592,782. Filing ↗machine: span 660264–660274
3Section 01, Pablo CagnoniDEF 14A2026-04-280000879169-26-000031Section “Summary Compensation Table”. As printed: 8,838,961. Filing ↗machine: r6 · c30 · span 650737–650746
4Section 01, Herve HoppenotDEF 14A2026-04-280000879169-26-000031Section “Summary Compensation Table”. As printed: 6,380,525. Filing ↗machine: t91 · r3 · c16 · span 641487–641496
5Section 01, Steven SteinDEF 14A2026-04-280000879169-26-000031Section “Summary Compensation Table”. As printed: 6,304,172. Filing ↗machine: r10 · c30 · span 663627–663636
6Section 01, Christiana StamoulisDEF 14A2026-04-280000879169-26-000031Section “Summary Compensation Table”. As printed: 4,936,550. Filing ↗machine: r13 · c30 · span 672876–672885
7Section 01, Thomas TrayDEF 14A2026-04-280000879169-26-000031Section “Summary Compensation Table”. As printed: 990,368. Filing ↗machine: r16 · c30 · span 682687–682694
8Section 03, William Meury PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r6 · c23 · span 751118–751127
9Section 03, Thomas Tray PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r38 · c12 · span 827154–827159
10Section 03, Pablo Cagnoni OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r16 · c21 · span 775094–775101
11Section 03, Mohamed Issa PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r23 · c23 · span 791975–791984
12Section 03, Mohamed Issa PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r24 · c21 · span 794174–794181
13Section 03, Mohamed Issa RSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r20 · c21 · span 784652–784661
14Section 03, Christiana Stamoulis PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r34 · c21 · span 818355–818362
15Section 03, Steven Stein PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r28 · c23 · span 804062–804071
16Section 03, Christiana Stamoulis PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r33 · c23 · span 816155–816164
17Section 03, Hervé Hoppenot OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r10 · c21 · span 760644–760651
18Section 03, Hervé Hoppenot OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r9 · c21 · span 758279–758288
19Section 03, Hervé Hoppenot PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r13 · c21 · span 767961–767968
20Section 03, Hervé Hoppenot PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r12 · c23 · span 765762–765771
21Section 03, Mohamed Issa PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r21 · c21 · span 786852–786861
22Section 03, Steven Stein PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r29 · c21 · span 806262–806269
23Section 03, Mohamed Issa OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r22 · c15 · span 788325–788331
24Section 03, Thomas Tray OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r36 · c21 · span 823151–823157
25Section 03, William Meury PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r5 · c23 · span 748356–748366
26Section 03, Christiana Stamoulis OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r32 · c21 · span 813397–813404
27Section 03, Pablo Cagnoni PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r18 · c21 · span 780052–780061
28Section 03, William Meury RSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r7 · c21 · span 753317–753326
29Section 03, Pablo Cagnoni PSUDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r17 · c23 · span 777852–777861
30Section 03, Steven Stein OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r26 · c21 · span 798941–798948
31Section 03, William Meury OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r4 · c15 · span 744702–744709
32Section 03, Thomas Tray OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r37 · c21 · span 825512–825518
33Section 03, Christiana Stamoulis OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r31 · c21 · span 811034–811041
34Section 03, Steven Stein OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r27 · c21 · span 801304–801311
35Section 03, Pablo Cagnoni OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r15 · c21 · span 772731–772738
36Section 03, Hervé Hoppenot OPTIONDEF 14A2026-04-280000879169-26-000031Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t95 · r11 · c21 · span 763007–763012
37Section 07, pay ratioDEF 14A2026-04-280000879169-26-000031Section “CEO Pay Ratio”. As printed: 110.47 : 1. Filing ↗machine: span 1232682–1232693
38Section 08, Julian C. BakerDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 573,138. Filing ↗machine: span 307703–307949
39Section 08, Edmund P. HarriganDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 539,638. Filing ↗machine: span 316088–316333
40Section 08, Paul J. ClancyDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 538,138. Filing ↗machine: span 312735–312980
41Section 08, Jean-Jacques BienaiméDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 536,138. Filing ↗machine: span 309389–309634
42Section 08, Jacqualyn A. FouseDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 524,638. Filing ↗machine: span 314411–314656
43Section 08, Susanne SchaffertDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 523,138. Filing ↗machine: span 319870–320150
44Section 08, Otis W. BrawleyDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 511,138. Filing ↗machine: span 311062–311307
45Section 08, Katherine A. HighDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 511,138. Filing ↗machine: span 317763–318008
46Section 08, William J. MeuryDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 0. Filing ↗
47Section 08, Hervé HoppenotDEF 14A2026-04-280000879169-26-000031Section “Director Compensation”. As printed: 0. Filing ↗
48Section 02, Suketu Upadhyay 2026-05-04Form 42026-05-060001533149-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Suketu Upadhyay 2026-05-04Form 42026-05-060001533149-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Suketu Upadhyay 2026-05-04Form 42026-05-060001533149-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Steven Stein 2026-05-06Form 42026-05-200001673776-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Pablo Cagnoni 2026-05-06Form 42026-05-200001205703-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, BAKER BROS. ADVISORS LP 2026-05-08Form 42026-05-110001193125-26-216988Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, BAKER BROS. ADVISORS LP 2026-05-08Form 42026-05-110001193125-26-216988Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, BAKER BROS. ADVISORS LP 2026-05-08Form 42026-05-110001193125-26-216988Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, BAKER BROS. ADVISORS LP 2026-05-08Form 42026-05-110001193125-26-216988Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Paul J. Clancy 2026-05-19Form 42026-05-210001409601-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Paul J. Clancy 2026-05-19Form 42026-05-210001409601-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Paul J. Clancy 2026-05-19Form 42026-05-210001409601-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Jean Jacques Bienaime 2026-05-26Form 42026-05-280001221590-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Jean Jacques Bienaime 2026-05-26Form 42026-05-280001221590-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Jean Jacques Bienaime 2026-05-26Form 42026-05-280001221590-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Thomas Tray 2026-05-26Form 42026-05-280001912317-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Pablo Cagnoni 2026-06-01Form 42026-06-030001205703-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Thomas Tray 2026-06-04Form 42026-06-080001912317-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Thomas Tray 2026-06-04Form 42026-06-080001912317-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Thomas Tray 2026-06-04Form 42026-06-080001912317-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Otis W. Brawley 2026-06-08Form 42026-06-100001213029-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Otis W. Brawley 2026-06-08Form 42026-06-100001213029-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Katherine A. High 2026-06-08Form 42026-06-100001631248-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Katherine A. High 2026-06-08Form 42026-06-100001631248-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Jean Jacques Bienaime 2026-06-08Form 42026-06-100001221590-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Jean Jacques Bienaime 2026-06-08Form 42026-06-100001221590-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Paul J. Clancy 2026-06-08Form 42026-06-100001409601-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Jacqualyn A. Fouse 2026-06-08Form 42026-06-100001405288-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Paul J. Clancy 2026-06-08Form 42026-06-100001409601-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Edmund P. Harrigan 2026-06-08Form 42026-06-100001177917-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, BAKER BROS. ADVISORS LP 2026-06-08Form 42026-06-100001193125-26-265952Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, BAKER BROS. ADVISORS LP 2026-06-08Form 42026-06-100001193125-26-265952Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, BAKER BROS. ADVISORS LP 2026-06-08Form 42026-06-100001193125-26-265952Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Jacqualyn A. Fouse 2026-06-08Form 42026-06-100001405288-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Edmund P. Harrigan 2026-06-08Form 42026-06-100001177917-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, BAKER BROS. ADVISORS LP 2026-06-08Form 42026-06-100001193125-26-265952Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, BAKER BROS. ADVISORS LP 2026-06-30Form 42026-07-020001193125-26-294712Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, BAKER BROS. ADVISORS LP 2026-06-30Form 42026-07-020001193125-26-294712Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Paul J. Clancy 2026-06-30Form 42026-07-020001409601-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Edmund P. Harrigan 2026-06-30Form 42026-07-020001177917-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Steven Stein 2026-07-02Form 42026-07-070001673776-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, William Meury 2026-07-02Form 42026-07-070001536778-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Thomas Tray 2026-07-02Form 42026-07-070001912317-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Patrick A. Mayes 2026-07-02Form 42026-07-070002079962-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Steven Stein 2026-07-14Form 42026-07-160001673776-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Thomas Tray 2026-07-14Form 42026-07-160001912317-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Patrick A. Mayes 2026-07-14Form 42026-07-160002079962-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Pablo Cagnoni 2026-07-14Form 42026-07-160001205703-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Mohamed Issa 2026-07-15Form 42026-07-160002050035-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Steven Stein 2026-07-15Form 42026-07-160001673776-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Steven Stein 2026-07-15Form 42026-07-160001673776-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Patrick A. Mayes 2026-07-15Form 42026-07-160002079962-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Pablo Cagnoni 2026-07-15Form 42026-07-160001205703-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Thomas Tray 2026-07-15Form 42026-07-160001912317-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Pablo Cagnoni 2026-07-16Form 42026-07-200001205703-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Mohamed Issa 2026-07-16Form 42026-07-200002050035-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, William Meury 2026-07-16Form 42026-07-200001536778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Richard A. Hoffman 2026-07-16Form 42026-07-200002098091-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Richard A. Hoffman 2026-07-16Form 42026-07-200002098091-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, David H. Gardner 2026-07-16Form 42026-07-200002085970-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, Mohamed Issa 2026-07-16Form 42026-07-200002050035-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Pablo Cagnoni 2026-07-16Form 42026-07-200001205703-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Pablo Cagnoni 2026-07-16Form 42026-07-200001205703-26-000021Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Steven Stein 2026-07-16Form 42026-07-200001673776-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Patrick A. Mayes 2026-07-16Form 42026-07-200002079962-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Steven Stein 2026-07-16Form 42026-07-200001673776-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Steven Stein 2026-07-16Form 42026-07-200001673776-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Thomas Tray 2026-07-16Form 42026-07-200001912317-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Thomas Tray 2026-07-16Form 42026-07-200001912317-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, William Meury 2026-07-16Form 42026-07-200001536778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, David H. Gardner 2026-07-16Form 42026-07-200002085970-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Patrick A. Mayes 2026-07-16Form 42026-07-200002079962-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, William Meury 2026-07-16Form 42026-07-200001536778-26-000009Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Richard A. Hoffman 2026-07-16Form 42026-07-200002098091-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Ramitpal K. Basi 2026-07-16Form 42026-07-200002083591-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Mohamed Issa 2026-07-16Form 42026-07-200002050035-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Steven Stein 2026-07-16Form 42026-07-200001673776-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Ramitpal K. Basi 2026-07-16Form 42026-07-200002083591-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, Patrick A. Mayes 2026-07-16Form 42026-07-200002079962-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, David H. Gardner 2026-07-16Form 42026-07-200002085970-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Ramitpal K. Basi 2026-07-16Form 42026-07-200002083591-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, Mohamed Issa 2026-07-16Form 42026-07-200002050035-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, Lee Heeson 2026-07-23Form 42026-07-270002039219-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Lee Heeson 2026-07-23Form 42026-07-270002039219-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Michael James Morrissey 2026-07-23Form 42026-07-270001780915-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, Michael James Morrissey 2026-07-23Form 42026-07-270001780915-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
151Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
152Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
153Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
154Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
155Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
156Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
157Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
158Section 02, Pablo Cagnoni 2026-07-31Form 42026-08-040001205703-26-000023Insider equity transaction reported since the proxy statement. Filing ↗
159Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
160Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
161Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
162Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
163Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
164Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
165Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
166Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
167Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
168Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
169Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
170Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
171Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
172Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
173Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
174Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
175Section 02, Patrick A. Mayes 2026-07-31Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
176Section 02, Patrick A. Mayes 2026-08-03Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
177Section 02, Patrick A. Mayes 2026-08-03Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
178Section 02, Patrick A. Mayes 2026-08-03Form 42026-08-040002079962-26-000013Insider equity transaction reported since the proxy statement. Filing ↗
179Section 02, Patrick A. Mayes 2026-08-05Form 42026-08-070002079962-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
180Section 02, Patrick A. Mayes 2026-08-05Form 42026-08-070002079962-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
181Section 02, Patrick A. Mayes 2026-08-05Form 42026-08-070002079962-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
182Section 02, Pablo Cagnoni 2026-08-05Form 42026-08-070001205703-26-000025Insider equity transaction reported since the proxy statement. Filing ↗
183Section 02, Pablo Cagnoni 2026-08-12Form 42026-08-140001205703-26-000027Insider equity transaction reported since the proxy statement. Filing ↗
184Section 02, Pablo Cagnoni 2026-08-19Form 42026-08-200001205703-26-000028Insider equity transaction reported since the proxy statement. Filing ↗
185Section 02, Ramitpal K. Basi 2026-08-25Form 42026-08-270002083591-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
186Section 02, Pablo Cagnoni 2026-09-15Form 42026-09-170001205703-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
187Section 02, Pablo Cagnoni 2026-09-15Form 42026-09-170001205703-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
188Section 02, Pablo Cagnoni 2026-09-15Form 42026-09-170001205703-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
189Section 02, Pablo Cagnoni 2026-09-15Form 42026-09-170001205703-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
190Section 02, Pablo Cagnoni 2026-09-15Form 42026-09-170001205703-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
191Section 02, Pablo Cagnoni 2026-09-15Form 42026-09-170001205703-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
192Section 02, Pablo Cagnoni 2026-09-15Form 42026-09-170001205703-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
193Section 02, Pablo Cagnoni 2026-09-15Form 42026-09-170001205703-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
194Section 02, Pablo Cagnoni 2026-09-15Form 42026-09-170001205703-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
195Section 02, Pablo Cagnoni 2026-09-15Form 42026-09-170001205703-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
196Section 02, David H. Gardner 2026-09-22Form 42026-09-240002085970-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
197Section 02, Paul J. Clancy 2026-09-30Form 42026-10-020001409601-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
198Section 02, Edmund P. Harrigan 2026-09-30Form 42026-10-020001177917-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
199Section 02, BAKER BROS. ADVISORS LP 2026-09-30Form 42026-10-020001193125-26-412653Insider equity transaction reported since the proxy statement. Filing ↗
200Section 02, BAKER BROS. ADVISORS LP 2026-09-30Form 42026-10-020001193125-26-412653Insider equity transaction reported since the proxy statement. Filing ↗
201Section 02, Lee Heeson 2026-10-01Form 42026-10-050002039219-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
202Section 02, Pablo Cagnoni 2026-10-15Form 42026-10-190001205703-26-000032Insider equity transaction reported since the proxy statement. Filing ↗
203Section 02, Pablo Cagnoni 2026-10-15Form 42026-10-190001205703-26-000032Insider equity transaction reported since the proxy statement. Filing ↗
204Section 02, Pablo Cagnoni 2026-10-15Form 42026-10-190001205703-26-000032Insider equity transaction reported since the proxy statement. Filing ↗
205Section 02, Pablo Cagnoni 2026-10-15Form 42026-10-190001205703-26-000032Insider equity transaction reported since the proxy statement. Filing ↗
206Section 02, Pablo Cagnoni 2026-10-15Form 42026-10-190001205703-26-000032Insider equity transaction reported since the proxy statement. Filing ↗
207Section 02, Pablo Cagnoni 2026-10-15Form 42026-10-190001205703-26-000032Insider equity transaction reported since the proxy statement. Filing ↗
208Section 02, Pablo Cagnoni 2026-10-15Form 42026-10-190001205703-26-000032Insider equity transaction reported since the proxy statement. Filing ↗
209Section 02, Pablo Cagnoni 2026-10-15Form 42026-10-190001205703-26-000032Insider equity transaction reported since the proxy statement. Filing ↗
210Section 02, Pablo Cagnoni 2026-10-15Form 42026-10-190001205703-26-000032Insider equity transaction reported since the proxy statement. Filing ↗
211Section 06, 2026 voteForm 8-K2026-06-090000879169-26-000043Item 5.07 · say-on-pay result. As reported: 83.86% (votes for as printed: 145,851,784). Filing ↗
212Section 06, 2025 voteForm 8-K2025-06-110000879169-25-000062Item 5.07 · say-on-pay result. As reported: 92.2% (votes for as printed: 153,838,972). Filing ↗
213Section 06, 2024 voteForm 8-K2024-06-140000879169-24-000082Item 5.07 · say-on-pay result. As reported: 89.59% (votes for as printed: 171,688,040). Filing ↗
214Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
215Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
216Section 09b board cost (computed)Computed——Cash 400,500 + equity 1,738,988 + all other 0 = 2,139,488, summed across the director compensation table rows.machine: formula: Σ = 2,139,488
217Exelixis, Inc., Section 10b CEO totalDEF 14A2026-04-150000939767-26-000046CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526
218INCYTE CORP (subject), Section 10b CEO totalDEF 14A2026-04-280000879169-26-000031CEO total compensation as printed in INCYTE CORP's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827
219Biogen Inc., Section 10b CEO totalDEF 14A2026-04-280001193125-26-187303CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391
220PTC Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-200001104659-26-045528CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. Filing ↗
221BioMarin Pharmaceutical Inc., Section 10b CEO totalDEF 14A2026-04-210001628280-26-026290CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915
222Moderna, Inc., Section 10b CEO totalDEF 14A2026-03-160001308179-26-000081CEO total compensation as printed in Moderna, Inc.'s own proxy. As printed: 19,932,217. Filing ↗machine: span 1132888–1132898
223Jazz Pharmaceuticals plc, Section 10b CEO totalDEF 14A2026-06-080001232524-26-000029CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379
224United Therapeutics Corporation, Section 10b CEO totalDEF 14A2026-04-290001082554-26-000009CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736
225BeOne Medicines Ltd., Section 10b CEO totalDEF 14A2026-04-280001104659-26-049655CEO total compensation as printed in BeOne Medicines Ltd.'s own proxy. As printed: 17,943,521. Filing ↗machine: t180 · r2 · c22 · span 1909011–1909021
226Natera, Inc., Section 10b CEO totalDEF 14A2026-04-230001104659-26-047770CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878
227Alnylam Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-060001628280-26-023923CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701
228Neurocrine Biosciences, Inc., Section 10b CEO totalDEF 14A2026-04-150000914475-26-000015CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957
229Illumina, Inc., Section 10b CEO totalDEF 14A2026-04-090001193125-26-149669CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536
230Section 10a, Neurocrine Biosciences, Inc. reciprocityDEF 14A—0000914475-26-000015Neurocrine Biosciences, Inc. names INCYTE CORP in its own disclosed peer group (read from its most recent proxy). Filing ↗
231Section 10a, Natera, Inc. reciprocityDEF 14A—0001104659-26-047770Natera, Inc. names INCYTE CORP in its own disclosed peer group (read from its most recent proxy). Filing ↗
232Section 10a, Moderna, Inc. reciprocityDEF 14A—0001308179-26-000081Moderna, Inc. names INCYTE CORP in its own disclosed peer group (read from its most recent proxy). Filing ↗
233Section 10a, PTC Therapeutics, Inc. reciprocityDEF 14A—0001104659-26-045528PTC Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include INCYTE CORP. Filing ↗
234Section 10a, Exelixis, Inc. reciprocityDEF 14A—0000939767-26-000046Exelixis, Inc. names INCYTE CORP in its own disclosed peer group (read from its most recent proxy). Filing ↗
235Section 10a, BeOne Medicines Ltd. reciprocityDEF 14A—0001104659-26-049655BeOne Medicines Ltd. names INCYTE CORP in its own disclosed peer group (read from its most recent proxy). Filing ↗
236Section 10a, Alnylam Pharmaceuticals, Inc. reciprocityDEF 14A—0001628280-26-023923Alnylam Pharmaceuticals, Inc. names INCYTE CORP in its own disclosed peer group (read from its most recent proxy). Filing ↗
237Section 10a, BioMarin Pharmaceutical Inc. reciprocityDEF 14A—0001628280-26-026290BioMarin Pharmaceutical Inc. names INCYTE CORP in its own disclosed peer group (read from its most recent proxy). Filing ↗
238Section 10a, Jazz Pharmaceuticals plc reciprocityDEF 14A—0001232524-26-000029Jazz Pharmaceuticals plc names INCYTE CORP in its own disclosed peer group (read from its most recent proxy). Filing ↗
239Section 10a, United Therapeutics Corporation reciprocityDEF 14A—0001082554-26-000009United Therapeutics Corporation names INCYTE CORP in its own disclosed peer group (read from its most recent proxy). Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the INCYTE CORP Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
INCY Peer Teardown Report